Entering text into the input field will update the search result below

Seattle Genetics initiates study of ADCETRIS/Opdivo in HL

Oct. 07, 2015 8:32 AM ETSeagen Inc. (SGEN) StockBMY, SGENBy: Douglas W. House, SA News Editor
  • Seattle Genetics (NASDAQ:SGEN) commences a Phase 1/2 clinical trial evaluating the combination of ADCETRIS (brentuximab vedotin) and Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in patients with relapsed/refractory Hodgkin lymphoma (HL) who have failed first-line treatment. The trial, which will enroll ~60 subjects, is being conducted to see if patient outcomes can be improved by combining ADCETRIS with a checkpoint inhibitor.
  • The study is being under the companies' clinical trial collaboration announced in January 2015.
  • ADCETRIS is an antibody-drug conjugate consisting of an anti-CD30 monoclonal antibody attached to microtubule disrupting agent, monomethyl auristatin E. It is currently cleared for the treatment of HL patients after failure of ASCT or after failure of at least two prior multi-agent chemo regimens and for the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemo regimen.
  • Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is approved in the U.S. for the treatment of metastatic squamous non-small cell lung cancer and metastatic melanoma.
  • Previously: Seattle Genetics and Bristol-Myers team up in blood cancer trials (Jan. 12)

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SGEN--
Seagen Inc.